Neurogenic

Company Overview

Snapshot

Founded in February 1995, Neurogenic operates with 1–10 employees. The company is currently in the Pre-Funding stage, developing sensitive immunoassays. In March 2019, Neurogenic announced a deal with SYnAbs for schizophrenia detection.

Business overview

Neurogenic is a clinical-stage diagnostics company focused on developing sensitive immunoassays for mental disorder diagnosis. The company's core technology involves an ELISA-based immunoassay designed to detect autoimmune Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients with early-onset schizophrenia symptoms. Neurogenic serves the healthcare and life sciences sectors, specifically targeting providers and laboratories with its diagnostic solutions.

Strategic signal

In March 2019, Neurogenic announced a deal with SYnAbs for schizophrenia detection. This collaboration is significant as it indicates a strategic partnership to advance the development and potential commercialization of Neurogenic's diagnostic technology, signaling progress in bringing its immunoassay for mental disorders to market.

Company Intelligence Q&A

What is Neurogenic's primary focus?

Neurogenic is a clinical-stage diagnostics company developing sensitive immunoassays to assist in the diagnosis of mental disorders.

When was Neurogenic founded?

Neurogenic was founded in February 1995.

What is the key product Neurogenic is developing?

Neurogenic is developing the Schizophrenia ELISA Diagnostic Assistant (SEDA) Assay, an ELISA-based immunoassay to detect Platelet-Associated Antibodies (PAA) for schizophrenia diagnosis.

What significant partnership did Neurogenic announce?

In March 2019, Neurogenic announced a deal with SYnAbs for schizophrenia detection, indicating a collaboration to advance its diagnostic technology.

What stage is Neurogenic currently in?

Neurogenic is currently in the Pre-Funding stage, with its product in clinical trials.